Active Ingredient History

NOW
  • Now
Mafenide is a sulfonamide-type medication used as an antibiotic. It is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds. Mafenide is not antagonized by pABA, serum, pus or tissue exudates, and there is no correlation between bacterial sensitivities to mafenide and to the sulfonamides. A single case of bone marrow depression and a single case of an acute attack of porphyria have been reported following therapy with mafenide acetate. Fatal hemolytic anemia with disseminated intravascular coagulation, presumably related to a glucose-6-phosphate dehydrogenase deficiency, has been reported following therapy with mafenide acetate. Other adverse reactions are: pain or burning sensation, rash and pruritis, erythema, skin maceration from prolonged wet dressings, facial edema, swelling, hives, blisters, eosinophilia.   NCATS

  • SMILES: NCc1ccc(cc1)S(=O)(=O)N
  • InChIKey: TYMRLRRVMHJFTF-UHFFFAOYSA-N
  • Mol. Mass: 186.24
  • ALogP: -0.21
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.3249 - $71.4560
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

4-(aminomethyl)benzenesulfonamide | 4-(aminosulfonyl)benzylamine | 4-homosufanilamide | 4-homosulfanilamide | 4-sulfamoylbenzylamine | ambamide | bensulfamide | benzamsulfonamide | homosulfanilamide | mafenide | mafenide acetate | m,afenide hcl | m,afenide hydrochloride | malfamin | maphenid | maphenide | maphenidum | p-sulfamoylbenzylamine | sulfamylon

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue